New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
06:35 EDTARWRArrowhead shares likely weak on lack of data, says Piper Jaffray
Piper Jaffray expects shares of Arrowhead to be under pressure following the company's Q3 results given the lack of data for ARC-520 for the treatment of hepatitis-B virus infection. Piper keeps an Overweight rating on the stock with a $24 price target.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
10:49 EDTARWRArrowhead strengthened position in RNAi with Novartis deal, says Piper Jaffray
After Arrowhead Research (ARWR) purchased Novartisí (NVS) RNAi R&D portfolio and associated assets for $35M in cash and stock, Piper Jaffray said it believes the deal further consolidates and strengthens Arrowhead's position in the RNAi space. The firm maintains its $12 price target and Overweight rating on Arrowhead shares.
08:01 EDTARWRArrowhead to host conference call
Subscribe for More Information
07:31 EDTARWRArrowhead acquires Novartis' RNAi research and development portfolio
Subscribe for More Information
February 23, 2015
07:33 EDTARWRArrowhead initiates dosing in phase 1 trial of ARC-AAT
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use